Earlier today
Nigerians in dire situation as pharmaceutical sector grapples with crisis over spiraling drug… Politics Nigeria01:26
Yesterday
Departure of GSK, P&G, others to force 20,000 Nigerians out of jobs Legit NG08:44 9-Dec-23
In the last 7 days
Delisting: Shareholders approve N17.42 for GSK buyback The Punch18:58 8-Dec-23
Setfirst Limited and SmithKline Beecham forego N2 Billion in favor of GSK Nigeria Shareholders Nairametrics17:41 8-Dec-23
GSK's Augmentin is India's no.1 drug brand The Times of India14:13 8-Dec-23
Reno Omokri tackles Peter Obi as P&G moves to leave Nigeria following GSK’s exit Legit NG13:47 8-Dec-23
GSK/P&G exit: Why investors are leaving Nigeria — Atedo Peterside Tribune Online11:54 8-Dec-23
Court ordered meeting: Shareholders approves delisting of GSK from NGX, to receive N17.42 per share Nairametrics09:52 8-Dec-23
Peter Obi Laments the Exit of Corporate Giants P&G, GSK, Others From Nigeria Report Afrique08:59 8-Dec-23
Drug imports in Nigeria rise by 68% by Q3 2023 over weak naira, GSK exit Nairametrics08:51 8-Dec-23
Earnings call: Veeva Systems surpasses Q3 expectations, plans expansion Investing.com08:34 8-Dec-23
3 Pharma Stocks Flashing 'Buy' Signals in December Entrepreneur Magazine08:20 8-Dec-23
GSK and GCOA report reveals global inequities in adult immunisation uptake PMLiVE07:28 8-Dec-23
GSK/P&G exit: Investors who value rule of law running away from Nigeria – Atedo Peterside Vanguard, Nigeria06:47 8-Dec-23
At £14, the GSK share price looks like a top bargain to me Motley Fool (UK)02:06 8-Dec-23
Obi laments multinational companies' exit, says Nigeria's investment profile not attractive The Punch17:24 7-Dec-23
GlaxoSmithKline completes VRS scheme as part of its business review The Business Standard13:23 7-Dec-23
Neca blames exit of P&G, others on infrastructure, policies Vanguard, Nigeria12:55 7-Dec-23
Wave makes $100M public offering after dosing first subjects with GSK-partnered RNA editing drug ENDPOINTS06:55 7-Dec-23
Unilever, GSK, 4 other major foreign companies that exited Nigeria in 2023 Legit NG06:41 7-Dec-23
'GSK's immunotherapy Jemperli paves way for 2nd-line endometrial cancer treatment' Korea Biomedical Review03:16 7-Dec-23
Following GSK’s Exit, P&G Moves to Leave Nigeria ThisDay Live23:17 6-Dec-23
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing… GlobeNewswire (Press Release)16:11 6-Dec-23
Primary Biliary Cholangitis Market to Register Stunning Growth by 2032, Predicts DelveInsight | Key Companies to Watch… GlobeNewswire (Press Release)13:09 6-Dec-23
After Sanofi, GSK, another consumer giant moves to dissolve operations in Nigeri... Legit NG10:30 6-Dec-23
New global analysis across five cities shows inequities in adult immunisation uptake, signalling need to redesign local … GlaxoSmithKline (Press Release)08:07 6-Dec-23
Cobolimab by GSK for Melanoma: Likelihood of Approval Pharmaceutical Technology21:48 5-Dec-23
Cobolimab by GSK for Colorectal Cancer: Likelihood of Approval Pharmaceutical Technology21:48 5-Dec-23
Gepotidacin mesylate by GSK for Uncomplicated Cervical And Urethral Gonorrhea: Likelihood of… Pharmaceutical Technology21:17 5-Dec-23
Cobolimab by GSK for Hepatocellular Carcinoma: Likelihood of Approval Pharmaceutical Technology20:37 5-Dec-23
GSK sees highest patent filings and grants during August in Q3 2023 Pharmaceutical Technology11:46 5-Dec-23
Novartis follows Pfizer, GSK, J&J and Sanofi as it launches a fresh corporate rebranding FiercePharma08:33 5-Dec-23
Is the flu shot market a slam dunk for mRNA vaccines? Experts aren’t so sure STAT04:34 5-Dec-23
GSK-6097608 by GSK for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval Pharmaceutical Technology23:52 4-Dec-23
Niraparib by GSK for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval Pharmaceutical Technology23:32 4-Dec-23
Niraparib by GSK for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval Pharmaceutical Technology23:32 4-Dec-23
Niraparib by GSK for Metastatic Colorectal Cancer: Likelihood of Approval Pharmaceutical Technology23:32 4-Dec-23
Niraparib by GSK for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval Pharmaceutical Technology23:32 4-Dec-23
Niraparib by GSK for Ovarian Cancer: Likelihood of Approval Pharmaceutical Technology22:10 4-Dec-23
Gepotidacin mesylate by GSK for Cystitis: Likelihood of Approval Pharmaceutical Technology12:19 4-Dec-23
Niraparib by GSK for Uveal Melanoma: Likelihood of Approval Pharmaceutical Technology12:09 4-Dec-23
Niraparib by GSK for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval Pharmaceutical Technology12:09 4-Dec-23
Niraparib by GSK for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval Pharmaceutical Technology12:09 4-Dec-23
Niraparib by GSK for Cervical Cancer: Likelihood of Approval Pharmaceutical Technology12:09 4-Dec-23
Niraparib by GSK for Gastric Cancer: Likelihood of Approval Pharmaceutical Technology12:09 4-Dec-23
Niraparib by GSK for Non-Small Cell Lung Cancer: Likelihood of Approval Pharmaceutical Technology11:59 4-Dec-23
Niraparib by GSK for Small-Cell Lung Cancer: Likelihood of Approval Pharmaceutical Technology11:59 4-Dec-23
Niraparib by GSK for Renal Cell Carcinoma: Likelihood of Approval Pharmaceutical Technology11:59 4-Dec-23
Niraparib by GSK for Astrocytoma: Likelihood of Approval Pharmaceutical Technology11:59 4-Dec-23
GSK RSV vaccine revenue to reach $1.26 billion in first year, CEO says Biopharma Reporter09:47 4-Dec-23
Quick Listen: Scrip's Five Must-Know Things Scrip Pharma Intelligence00:13 4-Dec-23
In the last month
Neuberg to raise $100 million pre-IPO funds The New Indian Express20:00 1-Dec-23
GSK, AstraZeneca, Johnson & Johnson and others raided in Turkish labour market probe Global Competition Review11:31 1-Dec-23
GSK Pulls Ahead of Pfizer in RSV Vaccine Market as Arexvy Nears Blockbuster Status BioSpace08:09 1-Dec-23
GSK global survey reveals misunderstandings about shingles in adults PMLiVE07:35 1-Dec-23
GSK shares data from global shingles survey Pharmafile06:04 1-Dec-23
As GSK's RSV shot nears blockbuster threshold, CEO sees plenty of 'headroom for growth' FiercePharma16:44 30-Nov-23
GSK is winning 70% of the RSV market, while Pfizer's launch has left it ‘disappointed’ so far ENDPOINTS13:22 30-Nov-23
After GSK, Sanofi, another foreign company to leave Nigeria, sells shares to loc... Legit NG11:36 30-Nov-23
LIVE: Reuters Newsmaker with Emma Walmsley, CEO of GlaxoSmithKline Reuters - YouTube11:08 30-Nov-23
Hallam apprentice wins sector’s highest honour Sheffield Hallam University10:36 30-Nov-23
GSK CEO says RSV vaccine revenue to top 1 bln pounds in first year Reuters10:29 30-Nov-23
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND Zacks10:08 30-Nov-23
A protein inhibited by GSK's Rukobia could be culprit behind HIV comorbidities, study suggests FierceBiotech09:41 30-Nov-23
After watching Merck's chronic cough drama, GSK knew exactly what not to do with Bellus asset FierceBiotech08:09 30-Nov-23
Luke Miels on GSK internal changes, ‘very busy’ BD scene ENDPOINTS07:25 30-Nov-23
New global survey finds widespread misunderstandings about shingles despite its lifetime prevalence GlaxoSmithKline (Press Release)04:16 30-Nov-23
GSK Korea holds event to raise HIV awareness Korea Biomedical Review00:46 30-Nov-23
Belantamab Mafodotin Improves PFS in Relapsed/Refractory Multiple Myeloma American Journal of Managed Care19:08 29-Nov-23
Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma Pharmacy Times11:53 29-Nov-23
Phosphorylation of USP27X by GSK3β maintains the stability and oncogenic functions of CBX2 Nature.com02:56 29-Nov-23
GSK’s consumer wing nears settlement of ‘non-drowsy’ marketing lawsuit FiercePharma11:20 28-Nov-23
Dental Care Market Will Hit Big Revenues In Future | Ultradent Products, GlaxoSmithKline, Young … Industry Today09:30 28-Nov-23
GSK shares positive phase 3 results for Blenrep combination in multiple myeloma PMLiVE07:41 28-Nov-23
Can GSK’s Blenrep Make A Comeback After Beating Darzalex? Eye Toxicity Concerns Remain Scrip Pharma Intelligence18:31 27-Nov-23
GSK’s Blenrep makes a comeback in multiple myeloma BioWorld17:06 27-Nov-23
Boost for GSK as blood cancer drug Blenrep hits key goal in a late-stage trial This is Money17:06 27-Nov-23
GSK's Blenrep Combo Meets PFS Endpoint in Head-to-Head Study Zacks12:38 27-Nov-23
After market withdrawal, GSK touts positive Blenrep combo trial in multiple myeloma FiercePharma10:56 27-Nov-23
GSK Builds Case for Blenrep’s Comeback with Promising Phase III Data BioSpace09:13 27-Nov-23
GSK Key Drugs & Vaccines Help Stock Outperform Industry YTD Zacks08:03 27-Nov-23
Sosei Heptares to take back GPCR agonist after GSK changes course ENDPOINTS07:23 27-Nov-23
Une entreprise biopharmaceutique de pointe adopte Veeva Vault CRM afin d'assurer l'engagement… PR Newswire (Press Release)07:04 27-Nov-23
Top Biopharma verpflichtet sich zu Veeva Vault CRM für globales Kundenengagement PR Newswire (Press Release)07:04 27-Nov-23
Top Biopharma Commits to Veeva Vault CRM for Global Customer Engagement PR Newswire (Press Release)07:04 27-Nov-23
Is GSK’s Blenrep heading for a renaissance? pharmaphorum06:36 27-Nov-23
GSK reports positive data from Phase III multiple myeloma trial Clinical Trials Arena06:12 27-Nov-23
GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment Pharmafile05:46 27-Nov-23
Sosei Heptares to regain rights to IBD treatment candidate from GSK Investing.com05:42 27-Nov-23
GSK jilts Sosei, dropping bowel disease asset on cusp of clinic amid changes at immunology unit FierceBiotech05:06 27-Nov-23
EU considers retracting Blenrep's authorisation after GSK trial Investing.com04:30 27-Nov-23
GSK announces positive results from Blenrep phase 3 blood cancer trial London South East04:06 27-Nov-23
GSK receives 'positive' headline results from phase III trial ShareCast04:05 27-Nov-23
GSK Blood Cancer Drug Blenrep Hits Goal in Late-Stage Trial European Pharmaceutical Manufacturer03:57 27-Nov-23
Sosei sees $3bn sales potential for GSK's IBD discard pharmaphorum03:53 27-Nov-23
GSK myeloma drug shows promise in hard-to-treat patient group Proactive Investors (UK)03:34 27-Nov-23
GSK Says Blood Cancer Drug Helped Patients in Study BNN Bloomberg03:33 27-Nov-23
GSK reports Blenrep outperforms in phase III multiple myeloma trial Investing.com03:19 27-Nov-23
GSK’s blood cancer drug shows promise in late-stage trial City AM03:17 27-Nov-23
GSK Reports Positive Results From DREAMM-7 Phase III Trial For Blenrep - Quick Facts RTT News02:32 27-Nov-23
GSK says blood cancer drug meets primary goal in late-stage trial Reuters02:24 27-Nov-23
GSK says multiple myeloma drug Blenrep extended progression-free survival in PhIII ENDPOINTS02:09 27-Nov-23
GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep in relapsed/refractory multiple… GlaxoSmithKline (Press Release)02:08 27-Nov-23
GSK Exit Sparks Inflation, Drives Drugs Prices In Persistent Surge Leadership, Nigeria08:13 26-Nov-23
Sosei Heptares Eyes $3bn Sales From IBD Drug Returned By GSK Scrip Pharma Intelligence11:26 24-Nov-23
GSK halts development of potential IBD drug GSK4381406 Investing.com08:21 24-Nov-23
Cameroon becomes first African Recipient of malaria vaccine as Nigeria anticipates turn Nairametrics07:43 24-Nov-23
Sosei to regain rights to IBD drug after GSK discontinues programme Pharmaceutical Technology06:23 24-Nov-23
Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for… GlobeNewswire (Press Release)03:40 24-Nov-23
PSN charges FG on local production of APIs Nigerian Guardian22:50 23-Nov-23
Meningitis Vaccine Market May See a Big Move | GlaxoSmithKline, Baxter International, Pfizer,… Industry Today07:12 22-Nov-23
Cameroon receives first shipment of GSK's Mosquirix malaria vaccine Reuters05:31 22-Nov-23
GSK plans low-carbon asthma inhaler in bid to cut emissions This is Money17:32 21-Nov-23
GSK propels its progress to Net Zero European Pharmaceutical Review12:55 21-Nov-23
GSK aims to slash carbon emissions with next-generation inhaler FiercePharma10:25 21-Nov-23

      
            
      
    view more headlines
   
      
      
      
10 Dec 01:26
   
GlaxoSmithKline News

NewsNow aims to be the world's most accurate and comprehensive aggregator of GlaxoSmithKline news, covering the latest share price, company announcements, vaccine trials, product news and more from the best online publications. Every story from every site is brought to you automatically and continuously 24/7, within around 10 minutes of publication.
GlaxoSmithKline

Latest News

GlaxoSmithKline News

Pharmaceuticals Top Stories

Business Top Stories
